Stockscreener 앱 받기
6.885
0.51%
-0.035
시간 외 거래:
6.88
-0.005
-0.07%
전일 마감가:
$6.92
열려 있는:
$6.93
하루 거래량:
8,342
Relative Volume:
0.44
시가총액:
$27.85M
수익:
$8.30M
순이익/손실:
$-52.26M
주가수익비율:
0.175
EPS:
39.3379
순현금흐름:
$-17.14M
1주 성능:
-1.22%
1개월 성능:
-8.20%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$6.75
$7.2008
1주일 범위
$6.72
$7.2008
52주 변동 폭
$6.72
$9.58
Kyntra Bio Inc Stock (KYNB) Company Profile
명칭
Kyntra Bio Inc
전화
415-978-1200
주소
350 BAY STREET, SAN FRANCISCO
Compare KYNB vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KYNB
Kyntra Bio Inc
|
6.885 | 27.99M | 8.30M | -52.26M | -17.14M | 39.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Kyntra Bio Inc Stock (KYNB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-08-08 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2023-06-26 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-06-26 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2023-06-26 | 다운그레이드 | Stifel | Buy → Hold |
| 2023-06-26 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-06-02 | 업그레이드 | Stifel | Hold → Buy |
| 2023-01-31 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2023-01-26 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2023-01-05 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2021-09-22 | 다운그레이드 | Goldman | Neutral → Sell |
| 2021-08-20 | 업그레이드 | Raymond James | Underperform → Mkt Perform |
| 2021-07-16 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-07-16 | 다운그레이드 | Stifel | Buy → Hold |
| 2021-04-07 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2021-04-07 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2021-03-31 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2021-03-02 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-02-01 | 개시 | H.C. Wainwright | Buy |
| 2020-10-26 | 개시 | Raymond James | Underperform |
| 2020-07-10 | 재개 | Stifel | Buy |
모두보기
Kyntra Bio Inc 주식(KYNB)의 최신 뉴스
KYNB Price History for Kyntra Bio Stock - Barchart.com
KYNB | Kyntra Bio, Inc. Common Institutional Ownership - Quiver Quantitative
Kyntra Bio reports prostate cancer trial results at ASCO GU - Investing.com South Africa
What's Going On With Kyntra Bio Stock Tuesday? - Bitget
Kyntra Bio announces positive data from Phase 1b/2 study of FG-3246 - TipRanks
Kyntra Bio reports prostate cancer trial results at ASCO GU By Investing.com - Investing.com Australia
KYNB to Present FG-3246 Trial Data at ASCO GU 2026 - GuruFocus
Kyntra Bio Announces Positive Data from the Investigator-Sponsored Phase 1b/2 Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer to Be Presented at ASCO GU 2026 - marketscreener.com
Kyntra Bio to Participate in Upcoming Investor Conferences - The Manila Times
Kyntra Bio Charts a New Course in Oncology - AD HOC NEWS
KYNB SEC FilingsKYNTRA BIO INC 10-K, 10-Q, 8-K Forms - Stock Titan
Arrowhead gains, Agios drops as drug developers end 2025 up 34% - BioWorld MedTech
KYNB Stock Price, Forecast & Analysis | KYNTRA BIO INC (NASDAQ:KYNB) - ChartMill
Kyntra Bio (KYNB) Stock Price, News & Analysis - MarketBeat
What is the current Price Target and Forecast for Kyntra Bio Inc (KYNB) - Zacks Investment Research
symbol__ Stock Quote Price and Forecast - CNN
KYNB: Kyntra Bio IncFull Company Report - Zacks Investment Research
FibroGen rebrands as Kyntra Bio, refocuses on oncology - TipRanks
FibroGen announces rebrand as Kyntra Bio - TipRanks
FibroGen stock rises after announcing rebrand to Kyntra Bio - Investing.com
FibroGen (FGEN) Transforms into Kyntra Bio with a New Focus - GuruFocus
FibroGen rebrands as Kyntra Bio with new Nasdaq ticker KYNB - Investing.com
FibroGen, Inc. Rebrands to Kyntra Bio, Targeting Oncology and Rare Disease Therapeutics with New Nasdaq Trading Symbol "KYNB" - Quiver Quantitative
FibroGen Rebrands as Kyntra Bio to Reflect a New Era of Focus and Momentum - GlobeNewswire
Is FibroGen (NASDAQ:FGEN) A Risky Investment? - simplywall.st
Roxadustat Granted Orphan Drug Designation for the - GlobeNewswire
FibroGen to Present at the Oppenheimer Movers in Rare Disease Summit - GlobeNewswire
FibroGen Sells China Unit To AstraZeneca And Refocuses - Finimize
FibroGen (NASDAQ: FGEN) sets Q3 results; 5:00 PM ET conference call Monday - Stock Titan
FibroGen Completes Sale of FibroGen China to AstraZeneca for Approximately $220 Million - GlobeNewswire
Major Regulatory Win: FibroGen's $815M China Business Sale to AstraZeneca Gets Green Light from Regulators - Stock Titan
FibroGen Second Quarter 2025 Earnings: Misses Expectations - simplywall.st
FGENFibrogen Inc Latest Stock News & Market Updates - Stock Titan
FibroGen Announces 1-for-25 Reverse Stock Split - GlobeNewswire
FibroGen Appoints Michael Kauffman, M.D., Ph.D. to its Board of Directors - marketscreener.com
FibroGen: Q1 Earnings Snapshot - marketscreener.com
FGEN Stock Price, News & Analysis - Stock Titan
Investors Don't See Light At End Of FibroGen, Inc.'s (NASDAQ:FGEN) Tunnel And Push Stock Down 26% - simplywall.st
FibroGen to Participate in the 24th Annual Needham Virtual Healthcare Conference - marketscreener.com
FGEN Stock: Price, Forecast, Financials & AI Analysis - Intellectia AI
FibroGen: Q4 Earnings Snapshot - marketscreener.com
FibroGen to Report Fourth Quarter and Full Year 2024 Financial Results - marketscreener.com
FibroGen, Inc. Announces Cessation of Christine L. Chung as Senior Vice President, China Operations - marketscreener.com
FibroGen, Inc. Appoints David DeLucia as Chief Financial Officer - marketscreener.com
FibroGen: Q3 Earnings Snapshot - marketscreener.com
FibroGen to Report Third Quarter 2024 Financial Results - marketscreener.com
Kyntra Bio Inc (KYNB) Stock Price Quote Today & Current Price Chart - Capital.com
FibroGen to Present at the H.C. Wainwright 26th Annual Global Investment Conference - marketscreener.com
FibroGen: Q2 Earnings Snapshot - marketscreener.com
FibroGen to Report Second Quarter 2024 Financial Results - marketscreener.com
FibroGen to Present at Goldman Sachs 45th Annual Global Healthcare Conference - marketscreener.com
Kyntra Bio Inc (KYNB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Kyntra Bio Inc 주식 (KYNB) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Wettig Thane | CEO |
Nov 13 '25 |
Buy |
9.18 |
1,000 |
9,180 |
22,239 |
| Schoeneck James A | Director |
Jun 30 '25 |
Buy |
5.07 |
23,567 |
119,485 |
39,666 |
| Wettig Thane | CEO |
Mar 24 '25 |
Buy |
0.35 |
145,000 |
50,663 |
543,329 |
| Schoeneck James A | Director |
Mar 20 '25 |
Buy |
0.35 |
250,000 |
88,000 |
323,722 |
| Schoeneck James A | Director |
Mar 21 '25 |
Buy |
0.34 |
50,000 |
17,040 |
373,722 |
3.69%
0.68%
자본화:
|
볼륨(24시간):